Where can I learn more about this study?
You can find more information about this study on the websites listed below. If
more information about the study results is available, it can also be found here.
X www.clinicaltrials.gov. Once you are on the website, type “NCT03328273”
into the search box and click “Search”.
X www.clinicaltrialsregister.eu. Once you are on the website, click “Home
and Search”, then type “2016-003737-15” in the search box and click
“Search”.
X www.AstraZenecaClinicalTrials.com. Once you are on the website, type
“ACE-CL-110” into the search box and click “Find a Study”.
Full Study Title: A Phase 1/2 Proof-of-Concept Study Investigating AZD6738
Monotherapy and Acalabrutinib in Combination with AZD6738 (ATR inhibitor) in
Subjects with Relapsed or Refractory High-Risk Chronic Lymphocytic Leukemia
(CLL).
Acerta Pharma BV Protocol Number: ACE-CL-110
National Clinical Trials Number: NCT03328273
EudraCT Number: 2016-003737-15
Acerta Pharma BV, a member of the AstraZeneca Group of companies,
sponsored this study and has its headquarters in Oss, the Netherlands.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants belong to a large community of people who take
part in clinical research around the world. They help researchers answer
important health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization
focused on educating and informing the public about clinical research participation. CISCRP is not involved
in recruiting participants for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2022_05_20
12 | Clinical Study Results